Synthesis of Novel 4-[1-(4-fluorobenzyl)-5-imidazolyl] Dihydropyridines and Studying their Effects on Rat Blood Pressure

Document Type: Original Article


1 Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

2 Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran


Calcium-channel blockers have an important role in the treatment of several cardiovascular disorders. Derivatives of 1, 4-dihydropyridine are one of the most potent calcium antagonists. In this study four novel ', 4-dihydropyridine calcium channel blockers were synthesized and their hypotensive properties were investigated in male rats.
Materials and Methods
Four 1, 4-dihydropyridines bearing 1-(4-fluorobenzyl)-5-imidazolyl substituent at 4 position (5a-d) were synthesized and tested for hypotensive activity in male rats. The animal was anaesthetized and the right jugular vein was cannulated for the administration of test agents. The left carotid artery was cannulated and connected to a pressure transducer for continuous monitoring of arterial blood pressure.
All synthesized compounds lowered rat blood pressure significantly in comparison with DMSO as vehicle and nifedipine as positive control. The hypotensive effects of all compounds were less than that of nifedipine at 2 and 4 mg/kg (P< 0.05). The order of their effects on mean arterial blood pressure (MABP) was 5b>5c>5a>5d at dose of 4 mg/kg (P< 0.05). All compounds tested increased heart rate in comparison with DMSO (P< 0.05). The chronotropic effect of nifedipine was significantly less than synthesized compounds at dose of 4 mg/kg (P< 0.01).
The results showed that these novels ', 4-dihydropyridines decreased mean arterial blood pressure (MABP) significantly, while increased heart rate in rat.


1.Weiner DA. Calcium channel blockers. Med Clin North Am 1988; 72: 83-115.

2.Mirkhani H, Omrani GR, Ghiaee S, Mahmoudian M. Effects of mebudipine and dibudipine, two new calcium- channel blockers, on rat left atrium, rat blood pressure and human internal mammary artery. J Pharm Pharmacol 1999; 51: 617-622.

3.Parmley WW. A delayed answer to the calcium blocker question. J Am Coll Cardiol 1996; 27:510-511.

4.Safak C, Simsek R. Fused 1,4-dihydropyridines as potential calcium modulatory compounds. Mini Rev Med Chem 2006; 6: 747-755.

5.Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 2007; 67:1309-1327.

6.Goldmann S, Stoltefuss J. 1,4-Dihydropyridines: Effects of chirality and conformation on the calcium antagonist and calcium agonist activities. Angew Chem Int Edit 1991; 30: 1559-1578.

7.Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50:560-586.

8.Hadizadeh F, Fatehi-Hassanabad Z, Fatehi-Hassanabad M, Beheshtizadeh A, Nabati F. Synthesis and antihypertensive activity of novel 4-[1-(4-X-benzyl)-5-imidazolyl] dihydropyridines in rat. Res Pharm Sci 2007; 2:87-93.

9.Meredith PA, Elliott HL. Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. J Hypertens 2004; 22:1641-1648.

10.Nekooeian AA, Khalili A, Javidnia K, Mehdipour AR, Miri R. Antihypertensive effects of some new nitroxyalkyl 1,4-dihydropyridine derivatives in rat model of two-kidney, one-clip hypertension. Iran J Pharm Res 2009; 8:193-199.

11.Langs DA, Strong PD, Triggle DJ. Receptor model for the molecular basis of tissue selectivity of 1, 4- dihydropyridine calcium channel drugs. J Comput Aided Mol Des 1990; 4:215-230.

12.Mager PP, Coburn RA, Solo AJ, Triggle DJ, Rothe H. QSAR, diagnostic statistics and molecular modelling of 1,4-dihydropyridine calcium antagonists: a difficult road ahead. Drug Des Discov 1992; 8: 273-289. 

13.Rovnyak GC, Kimball SD, Beyer B, Cucinotta G, DiMarco JD, Gougoutas J, et al. Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators. J Med Chem 1995; 38:119-129.

14.Hosseini M, Miri R, Amini M, Mirkhani H, Hemmateenejad B, Ghodsi S, et al. Synthesis, QSAR and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing 1-methyl-4,5-dichloroimidazolyl substituents. Arch Pharm (Weinheim) 2007; 340: 549-556.

15.Lavilla R. Recent developments in the chemistry of dihydropyridines. J Chem Soc Perkin Trans 1 2002: 1141-1156.

16.Hadizadeh F, Fatehi-Hassanabad Z, Bamshad M, Poorsoghat H, Fatehi-Hassanabad M. Synthesis and antihypertensive activity of new 1,4-dihydropyridines. Indian J Chem section B 2005; 44B:2343-2347.

17.Hadizadeh F, Fatehi M, Fatehi-Hassanabad Z, Zandieh M. Effects of 4-(2-Alkylthio-1-benzyl-5-imidazolyl)- Dihydropyridines on the isolated rat colon and right atrium contractility. Iran J Basic Med Sci 2005; 11:159-165.

18.Miri R, Javidnia K, Hemmateenejad B, Tabarzad M, Jafarpour M. Synthesis, evaluation of pharmacological activities and quantitative structure-activity relationship studies of a novel group of bis(4-nitroaryl-1,4- dihyropyridine). Chem Biol Drug Des 2009; 73:225-235.

19.Valdivielso JM, Macias JF, Lopez-Novoa JM. Cardiovascular effects of elgodipine and nifedipine compared in anaesthetized rats. Eur J Pharmacol 1997; 335:193-198.